SUBSEQUENT EVENTS (Details) - USD ($) $ in Thousands |
Apr. 30, 2024 |
Apr. 11, 2024 |
|---|---|---|
| Zynerba | Epygenix | ||
| Subsequent Event [Line Items] | ||
| Amount of fee payable upon achieving development and regulatory milestones | $ 130,000 | |
| Amount of fees payable upon achieving sale-based milestones | 515,000 | |
| Up front consideration | $ 35,000 | |
| Subsequent Events. | Bioprojet | Orexin-2 receptor agonist (OX2R) | ||
| Subsequent Event [Line Items] | ||
| Payment of upfront license fee | $ 25,500 | |
| Amount of fee payable upon achieving development and regulatory milestones | 127,500 | |
| Amount of fees payable upon achieving sale-based milestones | $ 240,000 |